组织陈列-产品详情

home > TISSUE ARRAYS > Multiple organ > MBC1902

Type
- FFPE
- FROZEN TISSUE
Identity
Organ
- Liver
- Esophagus
- Ovary
- Stomach
- Lung
- Colon
- Rectum
- Kidney
- Breast
- Endometrium
- Uterus
- Bladder
- Pancreas
- Skin
- Penis
- Testis
- Soft_Tissue
- Bone/Cartilage
- Oral/Cavity
- Bone/Marrow
- Heart
- Spleen
- Head/Neck
- Vulva
- Melanoma
- Appendix
- Intestine
- Adrenal Gland
- Thymus
- Fallopian tube
- Mouse
- Fetus
- Rat
- Monkey (Rhesus) (Normal)-RsFPT
- Monkey (Cynomolgus) (Normal)-CyFPT
- Dog
- Multiple organ
- Gall bladder and bile duct
- Esophagogastric junction
Types/Disease
Cores
Cases

Cores:

190

CASES:

190

Core Diameter(mm):

1

Thickness(µm):

5

Row number:

12

Column number:

16

Tissue Array Type:

FFPE

Species:

Human

MBC1902

$395.00

Description: Multiple organ carcinoma tissue array, including pathology grade, TNM and clinical stage, 190 cases/190 cores

Details: Multiple organ carcinoma tissue microarray, containing 38 cases each of stomach adenocarcinoma, hepatocellular carcinoma, ovary adenocarcinoma, endometrioid adenocarcinoma and squamous cell carcinoma of head and neck, single core per case

Applications: Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page

Please Select Tissue Array Type:

Unstained

H&E

Tag:

190 Cores 190 Cases Multiple organ multiple organs special price single core per case

Add To Cart

Outright purchase

Note

1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning.
2. Most TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). To prevent tissue detachment during antigen retrieval, unbaked slides must be baked for at least 30 to 120 minutes at 60°C. before putting into xylene for de-paraffinization. Baked slides were sent out baked for 2 hours.
In the following specsheet,“*” means invalid core; “-” means no applicable or negative in IHC markers."

Specification sheet
Overlapping case
Download specifications

Legend:

Car-Cardia Eso-Fsophagus

Malignant(-)
Malignant(I)
Malignant(IA)
Malignant(IB)
Malignant(IC)
Malignant(IIA)
Malignant(IIB)
Malignant(II)
Malignant(IIIA)
Malignant(IIIB)
Malignant(IIIC)
Malignant(III)
Malignant(IVA)

TISSUE ARRAYS
MBC1902

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
A	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto
B	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto
C	Sto	Sto	Sto	Sto	Sto	Sto	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
D	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
E	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Ova	Ova	Ova	Ova
F	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova
G	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova
H	Ova	Ova	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute
I	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute
J	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora
K	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora
L	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora

MBC1902

Age:
Sex:
Organ/Anatomic Site:
Pathology diagnosis:
Grade:
TNM:
Stage:
Tissue ID.:
Type:

Pos	No.	Age	Sex	Organ/Anatomic Site	Pathology diagnosis	Grade	TNM	Stage	Type	Tumor size	Ki-67	CK18
A1	1	53	M	Stomach	Adenocarcinoma	1	T4aN3bM0	IIIC	Malignant	1286	+,10%	++,60%
A2	2	57	M	Stomach	Adenocarcinoma	1	T3N2M0	IIIA	Malignant	864.5	+,15%	+++,100%
A3	3	57	M	Stomach	Adenocarcinoma	1	T3N0M0	IIA	Malignant	321.5	+,10%	++,80%
A4	4	65	M	Stomach	Adenocarcinoma	1	T3N1M0	IIB	Malignant	3*2	++,45%	++,90%
A5	5	38	F	Stomach	Adenocarcinoma	1--2	T3N2M0	IIIA	Malignant	-	+,5%	++,80%
A6	6	48	M	Stomach	Adenocarcinoma with necrosis	2	T3N2M0	IIIA	Malignant	-	++,25%	++,70%
A7	7	56	F	Stomach	Adenocarcinoma with necrosis	2	T3N2M0	IIIA	Malignant	-	+,15%	++,80%
A8	8	71	M	Stomach	Adenocarcinoma	2	T3N3aM0	IIIB	Malignant	95.54.5	++,35%	++,90%
A9	9	45	M	Stomach	Adenocarcinoma	2	T3N1M0	IIB	Malignant	5.04.00.5	+,15%	++,90%
A10	10	52	M	Stomach	Adenocarcinoma	2	T3N1M0	IIB	Malignant	5*4.5	-	+++,100%
A11	11	59	M	Stomach	Adenocarcinoma (sparse)	2	T3N1M0	IIB	Malignant	-	+，45%	+++,100%
A12	12	51	M	Stomach	Adenocarcinoma	2	T3N2M0	IIIA	Malignant	-	++,35%	++,100%
A13	13	63	F	Stomach	Adenocarcinoma with necrosis	2	T3N0M0	IIA	Malignant	15151	+,5%	+,60%
A14	14	56	F	Stomach	Adenocarcinoma	2	T3N2M0	IIIA	Malignant	1361	-	++,90%
A15	15	52	M	Stomach	Adenocarcinoma	2	T3N3aM0	IIIB	Malignant	-	-	+,60%
A16	16	41	F	Stomach	Adenocarcinoma	2--3	T3N0M0	IIA	Malignant	4.03.50.5	+,5%	++,90%
B1	17	42	M	Stomach	Adenocarcinoma	2--3	T3N0M0	IIA	Malignant	-	+,5%	+,90%
B2	18	58	M	Stomach	Adenocarcinoma with necrosis	2--3	T3N1M0	IIB	Malignant	1281.5	-	++,70%
B3	19	67	M	Stomach	Adenocarcinoma (interstitial)	2--3	T4aN0M0	IIB	Malignant	4.54.51	-	-
B4	20	67	M	Stomach	Adenocarcinoma with necrosis	3	T4aN0M0	IIB	Malignant	4.54.51	+，45%	++,80%
B5	21	59	F	Stomach	Adenocarcinoma (part mucinous adenocarcinoma)	3	T3N0M0	IIA	Malignant	1282	-	++,90%
B6	22	48	F	Stomach	Adenocarcinoma	3	T3N0M0	IIA	Malignant	-	++,55%	++,90%
B7	23	68	F	Stomach	Adenocarcinoma	3	T3N3aM0	IIIB	Malignant	1653.5	++,65%	++,80%
B8	24	60	F	Stomach	Adenocarcinoma with necrosis	3	T3N1M0	IIB	Malignant	-	+,5%	++,80%
B9	25	50	M	Stomach	Mucinous adenocarcinoma	3	T3N0M0	IIA	Malignant	6.54.50.5	+,35%	+,90%
B10	26	50	F	Stomach	Adenocarcinoma (sparse)	3	T3N0M0	IIA	Malignant	-	+,10%	++,80%
B11	27	58	M	Stomach	Adenocarcinoma	3	T3N0M0	IIA	Malignant	7.06.01.0	+,10%	+,70%
B12	28	58	M	Stomach	Adenocarcinoma	3	T3N3aM0	IIIB	Malignant	-	-	+++,100%
B13	29	31	F	Stomach	Adenocarcinoma	3	T3N3aM0	IIIB	Malignant	96.53.5	-	++,100%
B14	30	47	M	Stomach	Adenocarcinoma	3	T3N3bM0	IIIC	Malignant	5.03.50.5	+,15%	++,90%
B15	31	60	M	Stomach	Adenocarcinoma	3	T3N0M0	IIA	Malignant	-	++,40%	++,100%
B16	32	69	M	Stomach	Adenocarcinoma	3	T3N2M0	IIIA	Malignant	1564.5	+,5%	++,80%
C1	33	65	F	Stomach	Adenocarcinoma	3	T3N3aM0	IIIB	Malignant	-	+,10%	++,80%
C2	34	48	M	Stomach	Adenocarcinoma	3	T3N2M0	IIIA	Malignant	84.54.0	+,5%	++,90%
C3	35	39	F	Stomach	Adenocarcinoma with necrosis	3	T3N3aM0	IIIB	Malignant	186.53.5	+,15%	++,90%
C4	36	41	M	Stomach	Adenocarcinoma	3	T3N3aM0	IIIB	Malignant	3.53.00.5	-	++,90%
C5	37	70	M	Stomach	Adenocarcinoma	3	T3N1M0	IIB	Malignant	-	+,20%	+,30%
C6	38	55	M	Stomach	Mucinous adenocarcinoma	3	T3N1M0	IIB	Malignant	16*9	+，5%	++,60%
C7	39	41	M	Liver	Hepatocellular carcinoma	1	T2N0M0	II	Malignant	6.05.04.0	-	+,70%
C8	40	49	M	Liver	Hepatocellular carcinoma with necrosis	1	T2N0M0	II	Malignant	1032.5	-	+,40%
C9	41	43	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	-	+，5%	+,40%
C10	42	40	M	Liver	Hepatocellular carcinoma with cholangiocarcinoma	2	T3N1M0	IVA	Malignant	-	-	+++,100%
C11	43	45	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	6.06.04.5	-	++,40%
C12	44	27	M	Liver	Hepatocellular carcinoma (sparse)	2	T3N1M0	IVA	Malignant	11*11	-	-
C13	45	77	M	Liver	Hepatocellular carcinoma	2	T3aN0M0	IIIA	Malignant	6.05.05.0	+，5%	+,50%
C14	46	63	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	4.03.52.5	-	-
C15	47	51	M	Liver	Hepatocellular carcinoma	2	T3aN1M0	IVA	Malignant	6	-	+,40%
C16	48	58	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	776	-	+,10%
D1	49	48	M	Liver	Hepatocellular carcinoma	2	T3N0M0	IIIA	Malignant	864.5	+，2%	+,10%
D2	50	45	M	Liver	Hepatocellular carcinoma	2	T3N0M0	IIIA	Malignant	1284.5	++，20%	+,10%
D3	51	53	F	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	6.05.04.0	+,15%	+,80%
D4	52	54	F	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	127.53.5	-	+,10%
D5	53	48	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	-	+,15%	-
D6	54	53	F	Liver	Hepatocellular carcinoma	2	T1bN0M0	IB	Malignant	643	-	+,10%
D7	55	60	M	Liver	Hepatocellular carcinoma with necrosis	2	T3aN0M0	IIIA	Malignant	1194.5	-	+,50%
D8	56	37	M	Liver	Hepatocellular carcinoma	2	T3N0M0	IIIA	Malignant	86.54.5	+，10%	+,30%
D9	57	51	M	Liver	Hepatocellular carcinoma with degeneration	2	T3N0M0	IIIA	Malignant	965.5	-	+,50%
D10	58	65	M	Liver	Hepatocellular carcinoma	2	T3N0M0	IIIA	Malignant	15109	-	-
D11	59	51	F	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	842	-	-
D12	60	49	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	842	-	+,10%
D13	61	62	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	433	-	+,10%
D14	62	45	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	-	+，2%	-
D15	63	57	F	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	6.55.03.5	+，5%	++,70%
D16	64	32	M	Liver	Hepatocellular carcinoma	2	T2N0M0	II	Malignant	543	+，15%	-
E1	65	61	F	Liver	Hepatocellular carcinoma	2	T3N1M0	IVA	Malignant	-	-	+,10%
E2	66	72	F	Liver	Hepatocellular carcinoma	2--3	T2N0M0	II	Malignant	5.55.03.5	-	+,50%
E3	67	27	F	Liver	Hepatocellular carcinoma with degeneration	2--3	T4N0M0	IIIB	Malignant	-	-	-
E4	68	41	M	Liver	Hepatocellular carcinoma	3	T2N0M0	II	Malignant	-	+，2%	+,90%
E5	69	57	M	Liver	Hepatocellular carcinoma	3	T3N0M0	IIIA	Malignant	7.543	+，3%	+,30%
E6	70	57	M	Liver	Hepatocellular carcinoma	3	T3N0M0	IIIA	Malignant	1764	+，5%	+,60%
E7	71	38	M	Liver	Hepatocellular carcinoma with degeneration	3	T2N0M0	II	Malignant	-	-	+,40%
E8	72	51	M	Liver	Hepatocellular carcinoma	3	T3N0M0	IIIA	Malignant	1484.5	+，5%	+,30%
E9	73	52	F	Liver	Hepatocellular carcinoma	3	T2N0M0	II	Malignant	6.04.54.5	+，5%	+,10%
E10	74	49	M	Liver	Hepatocellular carcinoma with degeneration	3	T3N0M0	IIIA	Malignant	1084	-	+,20%
E11	75	47	M	Liver	Hepatocellular carcinoma with necrosis	3	T2N0M0	II	Malignant	3.52.52.2	-	-
E12	76	45	M	Liver	Hepatocellular carcinoma with degeneration	3	T2N0M0	II	Malignant	-	-	-
E13	77	29	F	Ovary	Serous papillary adenocarcinoma	1	T1N0M0	I	Malignant	-	+，15%	++,80%
E14	78	40	F	Ovary	Serous papillary adenocarcinoma	1	T1aN0M0	IA	Malignant	-	+，5%	++,90%
E15	79	41	F	Ovary	Serous papillary adenocarcinoma	1	T1N0M0	I	Malignant	642.5	+,5%	++,70%
E16	80	23	F	Ovary	Serous adenocarcinoma	1	T2bN0M0	IIB	Malignant	853	+,5%	++,90%
F1	81	45	F	Ovary	Serous papillary adenocarcinoma	1--2	T1aN0M0	IA	Malignant	-	+,10%	++,90%
F2	82	35	F	Ovary	Serous papillary adenocarcinoma (sparse)	2	T1cN0M0	IC	Malignant	15104	-	-
F3	83	75	F	Ovary	Serous papillary adenocarcinoma	2	T1aN0M0	IA	Malignant	-	+,45%	+,80%
F4	84	49	F	Ovary	Serous adenocarcinoma with necrosis	2	T1N0M0	I	Malignant	84.54	+,20%	++,80%
F5	85	53	F	Ovary	Serous adenocarcinoma	2	T3N0M0	III	Malignant	8.56.56	+,5%	++,90%
F6	86	39	F	Ovary	Serous adenocarcinoma with necrosis	2--3	T3cN0M0	IIIC	Malignant	644	+,15%	++,90%
F7	87	49	F	Ovary	Serous adenocarcinoma with necrosis	2--3	T1N0M0	I	Malignant	65.55	+,25%	++,90%
F8	88	79	F	Ovary	Serous adenocarcinoma	3	T1aN0M0	IA	Malignant	1486	+,15%	++,90%
F9	89	56	F	Ovary	Serous adenocarcinoma	3	T1N0M0	I	Malignant	653	+，5%	+,40%
F10	90	57	F	Ovary	Serous adenocarcinoma	3	T1N0M0	I	Malignant	954	+,5%	++,80%
F11	91	58	F	Ovary	Serous adenocarcinoma with necrosis	3	T1N0M0	I	Malignant	95.52	+,25%	+,40%
F12	92	51	F	Ovary	Serous adenocarcinoma	3	1bN0M0	IB	Malignant	862	+,5%	+,60%
F13	93	75	F	Ovary	Serous adenocarcinoma	2--3	T1N0M0	I	Malignant	983.3	+,10%	++,80%
F14	94	51	F	Ovary	Serous adenocarcinoma with necrosis	2--3	T1aN0M0	IA	Malignant	764	+,5%	++,80%
F15	95	43	F	Ovary	Serous adenocarcinoma	2--3	T3N0M0	III	Malignant	0.2	-	++,80%
F16	96	53	F	Ovary	Serous adenocarcinoma	3	T3N1M0	IIIA	Malignant	853	+，10%	++,60%
G1	97	55	F	Ovary	Serous adenocarcinoma	2	T1aN0M0	IA	Malignant	4.53.03.0	+,15%	++,80%
G2	98	41	F	Ovary	Serous adenocarcinoma (sparse)	3	T3N0M0	III	Malignant	-	++,35%	+,10%
G3	99	55	F	Ovary	Serous adenocarcinoma	2	T1cN0M0	IC	Malignant	9	+，5%	++,100%
G4	100	67	F	Ovary	Serous adenocarcinoma	2--3	T1aN0M0	IA	Malignant	965.5	+,5%	++,80%
G5	101	48	F	Ovary	Serous adenocarcinoma	3	T3aN0M0	IIIA	Malignant	4.54.53.5	+,25%	++,70%
G6	102	67	F	Ovary	Serous adenocarcinoma with necrosis	3	T1N0M0	I	Malignant	13126	++,35%	++,60%
G7	103	43	F	Ovary	Serous adenocarcinoma (interstitial)	*	T3cN0M0	IIIC	Malignant	874	-	癌少，++,90%
G8	104	37	F	Ovary	Serous adenocarcinoma	2--3	T1N0M0	I	Malignant	6.54.53.0	++,45%	++,80%
G9	105	49	F	Ovary	Serous adenocarcinoma with necrosis	2--3	T3N1M0	IIIA	Malignant	9	+,15%	++,90%
G10	106	58	F	Ovary	Serous adenocarcinoma with necrosis	3	T3cN0M0	IIIC	Malignant	-	-	++,90%
G11	107	58	F	Ovary	Serous adenocarcinoma	2--3	T3cN0M0	IIIC	Malignant	-	+,25%	++,90%
G12	108	56	F	Ovary	Serous adenocarcinoma	2	-	-	Malignant	-	+,5%	+++,100%
G13	109	52	F	Ovary	Serous adenocarcinoma	2--3	T3N0M0	III	Malignant	-	+,15%	++,80%
G14	110	50	F	Ovary	Serous adenocarcinoma	2--3	T2N1M0	IIIA	Malignant	-	+,5%	++,100%
G15	111	40	F	Ovary	Serous adenocarcinoma	3	-	-	Malignant	-	+，30%	++,70%
G16	112	47	F	Ovary	Serous adenocarcinoma with necrosis	3	T1aN1M0	IIIA	Malignant	-	+,2%	+,40%
H1	113	46	F	Ovary	Serous adenocarcinoma	2	T2bN1M0	IIIA	Malignant	-	+,3%	++,60%
H2	114	27	F	Ovary	Serous adenocarcinoma	2	T3cN0M0	IIIC	Malignant	-	+，15%	+++,100%
H3	115	34	F	Uterus	Endometrioid adenocarcinoma	1	T2aN0M0	II	Malignant	11103	+,10%	+,20%
H4	116	37	F	Uterus	Endometrioid adenocarcinoma	1	T1bN0M0	IB	Malignant	64.53	+，5%	++,60%
H5	117	45	F	Uterus	Endometrioid adenocarcinoma	1	T1aN0M0	IA	Malignant	-	+，5%	+++,90%
H6	118	48	F	Uterus	Endometrioid adenocarcinoma	1	T1aN0M0	IA	Malignant	-	+,30%	++,100%
H7	119	43	F	Uterus	Endometrioid adenocarcinoma	1--2	T1bN0M0	IB	Malignant	876	-	++,80%
H8	120	30	F	Uterus	Endometrioid adenocarcinoma	1--2	T1bN0M0	IB	Malignant	-	+，5%	+,80%
H9	121	57	F	Uterus	Endometrioid adenocarcinoma	1--2	T1aN0M0	IA	Malignant	4.03.00.5	+,15%	+,80%
H10	122	53	F	Uterus	Endometrioid adenocarcinoma	2	T1aN0M0	IA	Malignant	5.54.51.2	+，10%	+,50%
H11	123	47	F	Uterus	Endometrioid adenocarcinoma	2	T1bN0M0	IB	Malignant	4.03.52.5	-	+,30%
H12	124	49	F	Uterus	Endometrioid adenocarcinoma with necrosis	2	T2N0M0	II	Malignant	-	+,15%	++,60%
H13	125	54	F	Uterus	Endometrioid adenocarcinoma	2	T1aN0M0	IA	Malignant	963.5	+，5%	++,90%
H14	126	45	F	Uterus	Endometrioid adenocarcinoma	2	T1bN0M0	IB	Malignant	-	+，5%	+,30%
H15	127	35	F	Uterus	Endometrioid adenocarcinoma	2	T1bN0M0	IB	Malignant	3.53.01.5	+，15%	+,70%
H16	128	48	F	Uterus	Endometrioid adenocarcinoma with necrosis	2	T1aN0M0	IA	Malignant	963.5	+，25%	++,90%
I1	129	46	F	Uterus	Endometrioid adenocarcinoma	2	T1aN0M0	IA	Malignant	963.0	+,10%	++,80%
I2	130	46	F	Uterus	Endometrioid adenocarcinoma (sparse)	2	T1aN0M0	IA	Malignant	-	+，5%	++,70%
I3	131	52	F	Uterus	Endometrioid adenocarcinoma	2	T3aN0M0	IIIA	Malignant	874	+，5%	+,60%
I4	132	52	F	Uterus	Endometrioid adenocarcinoma	2	T1aN0M0	IA	Malignant	-	-	+,60%
I5	133	68	F	Uterus	Endometrioid adenocarcinoma with necrosis	2	T1bN0M0	IB	Malignant	744	+，10%	+,30%
I6	134	58	F	Uterus	Endometrioid adenocarcinoma	2	T1aN0M0	IA	Malignant	-	++，45%	+,80%
I7	135	54	F	Uterus	Endometrioid adenocarcinoma with necrosis	2	T1bN0M0	IB	Malignant	953	+，25%	+,60%
I8	136	47	F	Uterus	Endometrioid adenocarcinoma	2	T1bN0M0	IB	Malignant	10102.5	+，15%	+,40%
I9	137	52	F	Uterus	Endometrioid adenocarcinoma with necrosis	2	T1bN0M0	IB	Malignant	432	-	++,40%
I10	138	61	F	Uterus	Endometrioid adenocarcinoma	2	T1aN0M0	IA	Malignant	-	++，45%	++,80%
I11	139	52	F	Uterus	Endometrioid adenocarcinoma	2	T1aN0M0	IA	Malignant	432	+，25%	+,50%
I12	140	56	F	Uterus	Endometrioid adenocarcinoma	2	T1bN0M0	IB	Malignant	773	+，5%	++,90%
I13	141	64	F	Uterus	Endometrioid adenocarcinoma	2	T1bN0M0	IB	Malignant	963	+，5%	++,90%
I14	142	54	F	Uterus	Endometrioid adenocarcinoma with necrosis	2--3	T1bN0M0	IB	Malignant	643	+，10%	++,70%
I15	143	45	F	Uterus	Endometrioid adenocarcinoma	2	T1bN0M0	IB	Malignant	-	+，10%	++,80%
I16	144	50	F	Uterus	Endometrioid adenocarcinoma	2	T3aN0M0	IIIA	Malignant	884.5	-	++,60%
J1	145	51	F	Uterus	Endometrioid adenocarcinoma with degeneration	1--2	T1bN0M0	IB	Malignant	-	-	++,60%
J2	146	60	F	Uterus	Endometrioid adenocarcinoma	2	T2aN0M0	II	Malignant	-	+，25%	++,70%
J3	147	46	F	Uterus	Endometrioid adenocarcinoma	2--3	T3aN0M0	IIIA	Malignant	7.554	-	++,60%
J4	148	38	F	Uterus	Endometrioid adenocarcinoma	2--3	T3aN0M0	IIIA	Malignant	543	+，35%	++,80%
J5	149	63	F	Uterus	Endometrioid adenocarcinoma	3	T1aN0M0	IA	Malignant	765	+，20%	++,70%
J6	150	62	F	Uterus	Endometrioid adenocarcinoma	2--3	T1bN0M0	IB	Malignant	-	++，55%	++,80%
J7	151	66	F	Uterus	Endometrioid adenocarcinoma	3	T3N0M0	IIIA	Malignant	-	+，5%	++,80%
J8	152	50	F	Uterus	Endometrioid adenocarcinoma	3	T1bN0M0	IB	Malignant	553	+，5%	+,20%
J9	153	53	M	Oral cavity	Squamous cell carcinoma of tongue	1	T3N0M0	III	Malignant	5.5	+，5%	++,90%
J10	154	63	M	Oral cavity	Squamous cell carcinoma of tongue	1	T2N0M0	II	Malignant	54.53.0	+，10%	+++,90%
J11	155	45	M	Oral cavity	Squamous cell carcinoma of tongue	1	T4N1M0	IVA	Malignant	-	+，25%	++,90%
J12	156	44	M	Oral cavity	Squamous cell carcinoma of tongue	1	T2N1M0	III	Malignant	-	+，15%	+,70%
J13	157	30	M	Oral cavity	Squamous cell carcinoma of tongue	2	T3N0M0	III	Malignant	4.03.51.0	+,15%	++,90%
J14	158	47	F	Oral cavity	Squamous cell carcinoma of tongue	2	T2N0M0	II	Malignant	-	+,25%	+,60%
J15	159	49	F	Oral cavity	Squamous cell carcinoma of tongue	2	T2N0M0	II	Malignant	2.52.51.5	+,5%	++,90%
J16	160	40	M	Oral cavity	Squamous cell carcinoma of tongue	2--3	T2N0M0	II	Malignant	5.05.03.5	++,25%	+,70%
K1	161	45	M	Oral cavity	Squamous cell carcinoma of tongue (interstitial)	2--3	T2N1M0	III	Malignant	-	-	-
K2	162	46	F	Oral cavity	Squamous cell carcinoma of tongue base	1	T4aN0M0	IVA	Malignant	7	+,5%	++,60%
K3	163	50	M	Oral cavity	Squamous cell carcinoma of tongue base	2	T3N1M0	III	Malignant	63.53	++,35%	++,90%
K4	164	50	F	Oral cavity	Squamous cell carcinoma of tongue base with necrosis	2	T1N0M0	I	Malignant	-	-	+,40%
K5	165	73	M	Oral cavity	Squamous cell carcinoma of gums (interstitial)	1	T2N0M0	II	Malignant	853	-	+,60%
K6	166	60	M	Oral cavity	Squamous cell carcinoma of gums (interstitial)	1	T3N0M0	III	Malignant	-	+,15%	++,90%
K7	167	45	M	Oral cavity	Squamous cell carcinoma of gums	1	T3N0M0	III	Malignant	863.5	+，5%	++,80%
K8	168	55	M	Oral cavity	Squamous cell carcinoma of gums	1	T3N0M0	III	Malignant	-	+,15%	++,60%
K9	169	70	F	Oral cavity	Squamous cell carcinoma of mandibular gums with degeneration	1	T3N0M0	III	Malignant	-	+,5%	++,90%
K10	170	70	M	Oral cavity	Squamous cell carcinoma of gums	2	T2N0M0	II	Malignant	-	+,25%	+,60%
K11	171	60	M	Oral cavity	Squamous cell carcinoma of gums	1--2	T3N0M0	III	Malignant	863.5	+,2%	++,80%
K12	172	50	F	Oral cavity	Squamous cell carcinoma of gums	2	T3N0M0	III	Malignant	653	-	+,10%
K13	173	60	F	Oral cavity	Squamous cell carcinoma of lower lip	1	T2N0M0	II	Malignant	-	-	+,50%
K14	174	74	M	Oral cavity	Squamous cell carcinoma of lower lip	1	T1N0M0	I	Malignant	-	+，15%	+,60%
K15	175	61	M	Oral cavity	Squamous cell carcinoma of lower lip (hyperplasia)	*	T1N0M0	I	Malignant	53.52	+,15%	++,70%
K16	176	63	M	Oral cavity	Squamous cell carcinoma of lower lip	1	T2N0M0	II	Malignant	4.522	+,20%	++,60%
L1	177	80	M	Oral cavity	Squamous cell carcinoma of lower lip	1--2	T1N0M0	I	Malignant	3.63.32.5	+,15%	+,40%
L2	178	80	M	Oral cavity	Squamous cell carcinoma of epiglottis	1--2	T3N0M0	III	Malignant	643	+,5%	++,70%
L3	179	67	M	Oral cavity	Squamous cell carcinoma of epiglottis	2	T3N1M0	III	Malignant	553	-	++,80%
L4	180	50	M	Oral cavity	Squamous cell carcinoma of right parotid gland	2	T3N0M0	III	Malignant	554	+,25%	++,80%
L5	181	78	M	Oral cavity	Squamous cell carcinoma of parotid gland	2--3	T3N0M0	III	Malignant	8*8	+,3%	++,80%
L6	182	51	M	Oral cavity	Squamous cell carcinoma of bottom of the mouth	1	T3N0M0	III	Malignant	431	+，5%	++,80%
L7	183	58	M	Oral cavity	Squamous cell carcinoma of bottom of the mouth	1	T1N0M0	I	Malignant	-	+,5%	++,70%
L8	184	56	F	Oral cavity	Squamous cell carcinoma of bottom of the mouth	3	T2N0M0	II	Malignant	-	-	+,40%
L9	185	42	M	Oral cavity	Squamous cell carcinoma of cheek	3	T3N2M0	IVA	Malignant	-	+,5%	++,80%
L10	186	55	M	Oral cavity	Squamous cell carcinoma of left maxillary sinus	1	T3N0M0	III	Malignant	744	+,5%	++,60%
L11	187	51	F	Oral cavity	Squamous cell carcinoma of left maxillary sinus with necrosis	2	T2N0M0	II	Malignant	222	+,15%	++,70%
L12	188	54	M	Oral cavity	Squamous cell carcinoma of left maxillary sinus	2	T3N0M0	III	Malignant	-	+,5%	++,80%
L13	189	56	M	Oral cavity	Squamous cell carcinoma of right sinus piriformis	1	T2N0M0	II	Malignant	332	-	+,70%
L14	190	54	M	Oral cavity	Squamous cell carcinoma of left neck	3	T2N0M0	II	Malignant	-	+,15%	+,70%

Find overlapping cases with this tissue array:

MBC1902

File Format: .xls

Release Date: 2025-01-17 16:02:41
Download

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
A	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto
B	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto
C	Sto	Sto	Sto	Sto	Sto	Sto	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
D	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
E	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Ova	Ova	Ova	Ova
F	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova
G	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova
H	Ova	Ova	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute
I	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute
J	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora
K	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora
L	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
A	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto
B	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto
C	Sto	Sto	Sto	Sto	Sto	Sto	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
D	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
E	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Ova	Ova	Ova	Ova
F	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova
G	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova
H	Ova	Ova	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute
I	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute
J	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora
K	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora
L	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
A	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto
B	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto	Sto
C	Sto	Sto	Sto	Sto	Sto	Sto	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
D	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv
E	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Liv	Ova	Ova	Ova	Ova
F	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova
G	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova	Ova
H	Ova	Ova	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute
I	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute
J	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora
K	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora
L	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora	Ora